Compare HQI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | AGEN |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.6M | 274.8M |
| IPO Year | 2008 | 1999 |
| Metric | HQI | AGEN |
|---|---|---|
| Price | $17.48 | $8.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.00 | ★ $14.50 |
| AVG Volume (30 Days) | 21.9K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 73.08 | ★ 100.00 |
| EPS | 0.31 | ★ 0.96 |
| Revenue | $30,640,000.00 | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | $0.46 | N/A |
| P/E Ratio | $56.29 | ★ $8.71 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $7.38 | $2.71 |
| 52 Week High | $19.01 | $8.85 |
| Indicator | HQI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.20 | 61.86 |
| Support Level | $10.22 | $2.97 |
| Resistance Level | $19.01 | $8.76 |
| Average True Range (ATR) | 1.11 | 0.59 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 76.41 | 77.90 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.